Health Canada’s Natural Health Product Program Continues to Evolve
At the Pharmaceutical Sciences Group’s (PSG) 9th Annual Day with Health Canada Tuesday June 23, 2026, Karolina Zarichna from Source Nutraceutical, Inc. (SNI) attended discussions on the evolving direction of Canada’s Natural Health Product (NHP) regulatory framework.
Health Canada highlighted a continued shift toward a more risk-based and proportionate approach to NHP oversight. The focus is on balancing regulatory efficiency and reduced administrative burden while maintaining expectations for product safety, efficacy, and quality.
This discussion follows several years of significant activity within the NHP sector, including enhanced labelling requirements, expanded post-market authorities under Vanessa’s Law, and broader conversations on how regulatory resources should be prioritized.
- Why Is Health Canada Reassessing the NHP Regulatory Framework?
- Is Health Canada Changing the NHP Licensing Process?
- Are NHP Submission Requirements Changing?
- Are Health Canada’s NHP Labelling Requirements Changing?
- What Does This Mean for NHP Companies?
- Preparing for the Future of NHP Regulations in Canada
Why Is Health Canada Reassessing the NHP Regulatory Framework?
Since the Natural Health Products Regulations came into force in 2004, the Canadian NHP market has grown significantly in both volume and complexity.
Health Canada identified several challenges influencing the future direction of the program, including:
- Increased volume of Product Licence Applications (PLAs)
- More complex product formulations and claims
- Growing expectations for post-market oversight
- The need to focus regulatory resources where they provide the greatest benefit
Following the 2021 Auditor General’s report on NHPs, Health Canada introduced several initiatives aimed at strengthening oversight, including improvements to labelling requirements and expanded compliance tools.
More recently, discussions have shifted toward determining how oversight can remain effective while ensuring requirements remain proportionate to product risk.
Is Health Canada Changing the NHP Licensing Process?
A key topic discussed was whether the current licensing framework appropriately reflects the diversity of products regulated as NHPs.
Health Canada acknowledged that not all products present the same level of uncertainty. For example, products that fully align with established monographs generally have a different regulatory profile compared to products requiring a full scientific assessment.
As part of ongoing modernization discussions, Health Canada continues to evaluate opportunities to streamline lower-risk submissions, reduce duplication, and focus review resources on applications requiring greater assessment. One concept discussed is a potentially automated or simplified review process for lower-risk, monograph-aligned NHPs, which could allow Health Canada to better allocate resources toward higher-risk products requiring more intensive oversight.
For now, the current Natural Product Number (NPN) framework and processes remain in place, and companies should continue to follow existing Class I, Class II, and Class III submission pathways.
Are NHP Submission Requirements Changing?
Health Canada is also reviewing whether all information currently collected during pre-market review is necessary for making licensing decisions.
Recent discussions have focused on better aligning submission requirements with the information needed to support regulatory decision-making. The goal is to reduce unnecessary administrative burden by reassessing the submission of documents that may not directly inform the application review process, while ensuring this information remains available to demonstrate compliance when required.
Potential areas of modernization include:
- Reducing administrative requirements where appropriate
- Allowing certain compliance information to be maintained by companies rather than submitted upfront
- Reviewing whether some lower-risk amendments may be managed through notification processes
- Reducing duplication between pre-market review and post-market compliance activities
However, streamlined submissions should not be interpreted as reduced regulatory obligations. Companies remain responsible for maintaining the evidence, quality documentation, and compliance records needed to support the product throughout its lifecycle, including importation, release for sale, and post-market oversight.
Are Health Canada’s NHP Labelling Requirements Changing?
NHP labelling flexibility was another major area of discussion. Health Canada acknowledged industry feedback that highly prescriptive formatting requirements can create challenges, particularly for small packages and complex formulations.
Future approaches may focus more on achieving the intended outcome of clear, readable, consumer-friendly information rather than requiring one specific presentation format. In particular, Health Canada acknowledged that legibility and readability can often be achieved through practical label design elements, such as adequate white space, clear headings, appropriate font size, and sufficient contrast, rather than relying solely on a prescribed Product Facts Table (PFT) format.
Areas discussed included:
- Increased flexibility in label presentation
- Reassessment of PFT requirements, including whether the table format is always necessary to support consumer understanding
- Greater use of outcome-based labelling principles, where the focus is on whether information is clear and accessible
- Opportunities for digital labelling approaches where appropriate, such as using a QR code to support access to certain information that may not need to appear directly on the physical label at the point of purchase
The objective remains ensuring Canadians have access to important product information while allowing practical implementation by industry, particularly for small packages, complex formulations, and products with extensive ingredient or cautionary information.
What Does This Mean for NHP Companies?
For companies developing, importing, or marketing NHPs in Canada, the direction represents a shift toward greater efficiency, but not reduced responsibility.
Companies should continue prioritizing:
- Appropriate product classification
- Evidence to support claims
- Compliant formulation development
- Site licence planning
- Quality documentation
- Post-market compliance readiness
Health Canada’s approach appears to be moving away from a one-size-fits-all model toward oversight that better reflects product risk and regulatory certainty.
Preparing for the Future of NHP Regulations in Canada
The Canadian NHP framework continues to evolve, and companies should stay informed as Health Canada advances modernization initiatives.
While future changes may create opportunities for more efficient pathways, successful market access will continue to depend on strong regulatory strategy, quality systems, and lifecycle compliance planning.
SNI continues to support companies navigating NHP licensing, regulatory strategy, labelling compliance, and Canadian market access requirements. Fill out the form below to learn more about services and NHP solutions.
Book an introductory call using the following form:
